Skip to main content
. 2015 May 14;8:49. doi: 10.1186/s13045-015-0142-4

Figure 3.

Figure 3

The subgroup analysis for the association of serum CXCL13 with overall survival based on stage and EBV DNA positivity in blood. (A, B) High CXCL13 levels are associated with lower overall survival among patients with non-detectable EBV titers and stage I/II disease. (C, D) CXCL13 fails to predict prognosis in patients with advanced disease and detectable EBV titers.